Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 1, 2007

BMS Signs Research Services Agreement with Immunicon for Oncology Biomarker Development

  • Immunicon entered into a research services agreement with Bristol-Myers Squibb involving protein and molecular targets associated with circulating tumor cells.

    “Our collaborations span across protein biomarkers, phosphoproteins, and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs,” comments Leon Terstappen, M.D., Ph.D., CSO at Immunicon.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »